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ADAMTS: a disintegrin and metalloproteinase that harbours a thrombospon-
din motif.
CCN: the CCN family of proteins is a complex family of multifunctional proteins
with six members designated CCN1 to CCN6. The CCN acronym was
introduced in reference to the names of the first three members of the family
to be discovered: Cyr61 (cysteine-rich protein 61), CTGF (connective tissue
growth factor) and NOV (nephroblastoma overexpressed gene).
CT: C-terminal cysteine knot domain. This domain has a conserved pattern of
cysteines consistent with a six membered cysteine knot similar to several
members of the TGF-b growth factor family.
HSPGs: heparin sulphated proteoglycans – multifunctional molecules involved
in cell and protein adhesion and fine tuning regulatory proteins.
IGFBP: the insulin-like growth factor binding protein (IGFBP) family comprises
six IGFBPs (1–6) that bind insulin-like growth factors (IGFs) with high affinity
(KD 0.1 nM). IGFBPs exert their biological effects by modulating IGF
behaviour.
SMAD: small mothers against decapentaplegic – a family of transcription
factors that can modulate TGF-b behaviour.
TSP: the thrombospondin repeat domain is a 55 residue consensus sequence
named after the extracellular matrix glycoprotein thrombospondin-1 (TSP-1)
that contains repeats of three distinct domains within a primarily linear
structure. The TSP-1 domain binds a wide range of extracellular targets and
important signalling molecules including collagen V, fibronectin, TGF-b and
heparin.
VWC: von Willebrand factor C repeat domains, also referred to as chordin-like
cysteine-rich (CR) repeats, are an extremely common motif found in >500The CCN proteins are key signalling and regulatory
molecules involved in many vital biological functions,
including cell proliferation, angiogenesis, tumourigen-
esis and wound healing. How these proteins influence
such a range of functions remains incompletely under-
stood but is probably related to their discrete modular
nature and a complex array of intra- and inter-molecular
interactions with a variety of regulatory proteins and
ligands. Although certain aspects of their biology can be
attributed to the four individual modules that constitute
the CCN proteins, recent results suggest that some of
their biological functions require cooperation between
modules. Indeed, the modular structure of CCN proteins
provides important insight into their structure–function
relationships.
The CCN family of proteins
The CCN family of proteins is a complex family of multi-
functional proteins containing six members designated
CCN1 to CCN6. The CCN acronym was introduced from
the names of the first three members of the family to be
discovered: Cyr61 (cysteine-rich protein 61), CTGF (con-
nective tissue growth factor) and NOV (nephroblastoma
overexpressed gene) [1]. Owing to the multifunctional
nature of these proteins, they have been identified in
several other biological studies and have been assigned
multiple names; however, in this review we will use the
official nomenclature [2] (Table 1). (See also http://ccnso-
ciety.com). This family of secreted extracellular matrix
(ECM)-associated proteins is involved in a wide range of
important functional pathways, including adhesion, mito-
genesis, migration and chemotaxis, cell survival, differen-
tiation, angiogenesis, chondrogenesis, tumourigenesis and
wound healing. They have also been implicated in many
human diseases (for some comprehensive reviews, see
Refs [3–5]).
The unifying feature of this family of proteins is their
mosaic structure, consisting of discrete modules that share
identity with functional domains of other regulatory mol-
ecules. A prototypical CCN protein contains an N-terminal
secretory signal peptide and four functional domains: (i) an
insulin-like growth factor binding protein-like module
(IGFBP); (ii) a von Willebrand factor type C repeat
module (VWC); (iii) a thrombospondin type-1 repeat
module (TSP-1); and (iv) a cysteine-knot-containingCorresponding authors: Acharya, K.R. (bsskra@bath.ac.uk); Perbal, B.
(bperbal@gmail.com).
0968-0004  2008 Elsevier Ltd. All rights reserved. doi:10.1016/j.tibs.2008.07.006module (CT) (Figure 1). Apart from CCN5, which lacks a
CT module, all CCN proteins exhibit the same type of
organization and share a closely related primary structure,
which includes a series of 38 cysteine residues that are
strictly conserved in position and number. However, CCN6
lacks four cysteine residues in domain II (VWC).
The 38 cysteine residues that spread across the four
modules represent almost 10% of the CCN molecule by
mass. A short sequence that varies greatly in both compo-
sition and length among the CCN family members is
located directly after the VWC domain. It was proposed
to act as a hinge between the first and second half of the
molecule [1,3]. Recent data have established that each of
the linker regions that separate the four CCN modules is
susceptible to proteolysis [6]. Cleavage at these sites might
be responsible for the production of truncated molecules
and individual modules [4] that display distinct biological
properties. Moreover, these events might constitute an
additional process to regulate the biological activity of
the CCN proteins [5,7].
The six CCN family members share 30–50% identity
in their primary structure (40–60% similarity) [6,8].extracellular matrix proteins. This repeat typically comprises 70–100 amino
acids with ten conserved cysteine residues and a pair of cysteine-containing
motifs located in the sequence.
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Table 1. Nomenclature of the CCN family of proteinsa
CCN Family member Alternative names
CCN1 Cyr61, CTGF-2, IGFBP10, IGFBP-rP4
CCN2 CTGF, IGFBP8, IGFBP-rP2, HBGF-0.8 ecogenin
CCN3 NOV, NOVH, IGFBP9, IGFBP-rP3
CCN4 Wisp-1, Elm-1
CCN5 Wisp-2, CTGF-L, CTGF-3, HICP, Cop-1
CCN6 Wisp-3
aAbbreviations: Cyr61, cysteine rich 61; CTGF-2, connective tissue growth factor 2;
IGFBP-rP2, IGFBP-related protein 2; NOV, nephroblastoma overexpressed gene;
HBGF-0.8, heparin-binding growth factor 0.8; Wisp, Wnt-inducible secreted protein;
Elm-1, expressed in low metastatic cells; HICP, haparin-induced CCN-like protein;
Cop-1 card-only protein 1.
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(Figure 1), the CCN proteins share a common intron/exon
pattern, and each CCN family member contains five exons.
The first exon corresponds to the signal sequence, and the
remaining four exons correspond to one of the discrete
protein modules. This exon arrangement suggests a cer-
tain amount of ‘evolutionary shuffling’ of functional
domains that is also seen in other matricellular modular
proteins [1,6,9].
Although some CCN protein functions are directly
related to an individual functional module, many functions
are thought to result from modules acting in concert.
Truncated CCN2molecules, each comprising two modules,
can function independently to stimulate differentiation or
proliferation of fibroblast and to increase collagen syn-
thesis [10]. Production of truncated proteins showing
altered biological properties, or proteins without some
internal modules, has been associated with specific devel-
opmental stages and pathological situations [11].
The make-up of a single protein into four modules that
share identity with four large classes of regulatory
proteins, which play fundamental roles in cellular biology,
makes the CCN family members unique mosaic proteins.
The pleiotropic functions of the CCN proteins stem from
their tetramodular structure. However, a better knowledge
of the physical organization of the CCNproteins is required
to understand their crucial functions in both normal and
pathological conditions. This review summarizes the struc-
tural features of CCN proteins as they relate to their
diverse functions.
What are the biological roles of the CCN proteins?
The roles of CCN proteins as key regulatory ECM com-
ponents and as signalling molecules involved in important
biological functions have been covered in great detail in
other reviews [3,11]. The following sections will focus on
the biological properties of CCN proteins that appear to be
either common or specific to individual members of the
CCN family, to highlight possible relationships between
their biological function(s) and particular structural fea-
tures.
Adhesion and extracellular matrix remodelling
Adhesion, signalling and migration are processes in which
the CCN proteins might be involved, owing to the connec-
tion of CCN proteins to the ECM. CCN1 and CCN2 both
mediate adhesion in several types of cell [6]. In addition,
CCN2 is required for adhesion and ECM contraction [12].
Recently, it was reported that CCN3 activity increases the462adhesion of normal melanocytes to collagen type IV and
controls discoidin domain receptor 1 (DDR1)-mediated
three-dimensional localization of melanocytes in skin [13].
The ability of CCN proteins to promote adhesion
involves cell survival because interactions with several
surface integrins and transforming growth factor b
(TGF-b) can prevent cell apoptosis [6,14]. In addition to
interacting directly withECM components, including fibro-
nectin and heparin [6,12], CCN1 and CCN2 can induce
ECM synthesis and TGF-b-mediated fibronectin and col-
lagen expression via the induction of the SMAD (see Glos-
sary) family of transcription factors [6]. However, recent
data indicate that CCN2-dependent stimulation of col-
lagen and extracellular matrix synthesis in murine
embryonic fibroblasts does not involve the SMAD signal-
ling pathway [12,15].
Recombinant CCN3 induces adhesion of vascular
smooth muscle cells, endothelial cells and fibroblasts
through interactions with integrin cell surface receptors
and heparin sulphate proteoglycans [12]. Despite the
absence of an Arg-Gly-Asp (RGD) tripeptide cell adhesion
motif, which is often required for physical interaction with
integrins, CCN3 associates with the vitronectin receptor
avb3, integrins a5b1 and a6b1, possibly through its C-
terminal domain, and with integrins avb3, avb5, a2b1,
a3b1 and a7b1, which is consistent with the involvement of
a cell-type-dependent subset of adhesion molecules.
Skeletal development and chondrogenesis
Because integrins and other adhesive signalling molecules
perform vital roles in tissue remodelling [16], it is not
surprising that the CCN proteins are also involved in
skeletal formation and development [6,17]. All CCN family
members are involved in bone cell development and differ-
entiation (both osteoblasts and chondrocytes). Indeed,
their expression increases during fractures or breaks,
although the different family members appear to perform
distinct functions or are activated by different growth
factors [18]. In osteoblasts, for example, TGF-b signalling
increases CCN1, CCN2 and CCN5 expression but
decreases CCN4 expression [18]. CCN1, CCN2, CCN3
and CCN6 each induce the expression of chondrogenic
markers [12,17]. Recent studies performed using CCN2-
deficient cells have also provided new insights into the
roles that CCN2 might play in chondrogenesis [19]. In
addition to their chondrogenic functions, CCN1 and
CCN2 might also participate in cartilage neovasculariza-
tion through their involvement in angiogenesis [3].
Angiogenesis and wound repair
The growth of new blood vessels through angiogenesis is
important in tissue and cell development, tumour for-
mation and wound healing [6]. The CCN family members
are important angiogenic modulators owing to their inter-
actions with several growth factors and integrins [17]. In
particular, CCN1 and CCN2, the expression of which is
probably induced by growth factors, including fibroblast
growth factor (FGF) and TGF-b, mediate angiogenesis
through interactions with angiogenic integrins avb3 and
a6b1 [3,6,20]. However, in keeping with their status as
complex functional modulators, CCN proteins can promote
Figure 1. Arrangement of CCN domains. (a) A diagram showing the signal peptide (SP), insulin-like growth factor binding domain (IGFBP) in red, von Willebrand factor C
repeat (VWC) in blue, thrombospondin type-1 repeat (TSP-1) in yellow and cysteine knot (CT) in green. The protein is split into two halves separated by a variable ‘hinge’
region. Some of the known binding partners of each module are also listed: insulin-like growth factors (IGFs); bone morphogenic protein 4 (BMP4); transforming growth
factor b (TGF-b); LDL receptor protein 1 (LRP-1); and heparin sulphated proteoglycans (HSPGs). (b) A sequence alignment of the CCN protein family. The sections of the
sequence corresponding to each domain are shaded according to the colour scheme used in (a). The asterisks highlight the conserved residues and include the 38 cysteines
that form part of the key motifs of each domain. The three regions of the sequence that have been implicated directly in integrin binding are also highlighted. These areas
are highlighted in bold text. The V2 site binds integrin avb3 [104]; the T1 site binds a6b1 [105]; the H1 site also binds a6b1; and the H2 site binds HSPGs [106]. The alignment
was constructed by the T-Coffee server [107].
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actions with growth factors. For example, CCN2 can
promote angiogenesis through TGF-b-induced integrin
action [3], or it can suppress angiogenesis through inter-
actions with vascular endothelial growth factor (VEGF).
Notably, VEGF-dependent suppression can be alleviated
after matrix metalloprotease-mediated CCN2 cleavage
[12].
Although the angiogenic effects of CCN1, CCN2 and
CCN3 are beginning to be understood, the roles that CCN4,
CCN5 and CCN6 play in angiogenesis remain less clear
[17]. Differences in gene expressionmight play a role in the
distinct physiological roles of the CCN molecules: CCN1probably functions during early embryonic development;
CCN2 probably has a role in developmental processes that
occur later in life, including tissue regeneration; and CCN3
probably plays a supporting role. CCN1, CCN2 and CCN3
are induced during adult tissue repair [12]. The contri-
bution of CCN2 in scarring and the fibrotic response has
been reviewed in detail [12].
The role of CCN proteins in wound healing is probably
similar to the role they play in angiogenesis. The important
events in wound healing, for example chemotaxis, vascu-
larization, mitogenesis of fibroblasts, angiogenesis,
adhesion and ECM manipulation, are all regulated, in
part, by the CCN family. CCN1 and CCN2 are upregulated463
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sion also increases during liver regeneration [3,21]. By
contrast, in a mouse model of cutaneous wound healing,
CCN3 transcripts are rapidly reduced during the first
three days after wound formation or re-epithelialization
[20] when keratinocytes grow and migrate. Interestingly,
CCN3 production is induced in the epidermis and dermis 5
to 7 days after injury, when keratinocytes and fibroblasts
undergo redifferentiation to restore barrier function and
the dermal matrix, respectively [22].
Proliferation
Regulation of cell proliferation was one of the first bio-
logical functions assigned to CCN proteins. Indeed, CCN1
and CCN2 were initially described as proteins encoded by
an immediate early gene and a cysteine-rich mitogen,
respectively [3]. By contrast, it was initially proposed that
CCN3 acted as a growth inhibitor [11]. Over the past
decade, a wealth of experimental data has confirmed that
CCN1 and CCN2 activity stimulates cell proliferation.
However, as recombinant proteins, they do not affect cell
proliferation, nor can they potentiate the stimulatory
effects of other cytokines (for comprehensive reviews see
Refs [6,7,23]).
Apart from the antiproliferative effects of CCN3 that
have recently been documented at a mechanistic level [24],
very little is known regarding CCN protein signalling
pathways and targets that might account for their effects
on cell proliferation. Indeed, despite the many examples
that established a relationship between CCN2 expression
and growth stimulation, including its involvement of p44/
42 mitogen-activated protein kinase (MAPK)/extracellu-
lar-signal-regulated kinase (ERK) signalling pathway
[25], it was reported only recently that CCN2 knockout
mice display reduced cell proliferation and hypoplasia in
vivo [26]. CCN2 is also required for maximal ERK acti-
vation via syndecan 4 [27].
Interestingly, purified CCN2 domains exhibit differen-
tial effects on CCN2-dependent proliferative signalling
pathways [28]. In human umbilical vascular endothelial
cells (HUVECs), the VWC, TSP and CT domains, as well as
a full-length CCN2, efficiently activate the ERK signal
transduction cascade, whereas the IGFBP domain promi-
nently activates the Jun N-terminal kinase (JNK) path-
way. Interestingly, only a mixture of the four CCN2
domains could induce significant p38 MAPK activation
in human chondrocytic HCS-2/8 cells, as does the full-
length CCN2 protein.
Consistent with its expression being associated with
fibroblast quiescence [11], CCN3 elicits an inhibitory effect
in normal and pathological conditions, including tumour-
derived cells in which high CCN3 levels are detected and
associated with higher proliferation rates and/or high
tumourigenic potential [7,11,24,29,30]. Although growth
inhibitory functions have also been assigned to CCN5 [6]
and CCN6 [31], CCN3 remains the best example of a
negative regulator of cell growth in the CCN family.
Mechanistically, the CCN3 CT module is sufficient to
govern inhibition of cell growth [24], although recent data
indicate that other domains might be involved in this
process [32,33]. An explanation for the growth-inhibitory464effect of CCN3 was provided by the observation that CCN3
overexpression triggers an accumulation of cells at the
S-phase of the cell cycle [24]. Indeed, [3H]thymidine incorp-
oration increases in cells treated with recombinant CCN3
[11]. Likewise, the reduction in CCN3 levels observed
immediately after wounding or re-epithelialization (20)
is in agreement with the ability of CCN3 to negatively
regulate fibroblast proliferation. Interestingly CCN5,
which shows growth arrest activity, lacks a CT module.
CCN3-dependent growth inhibition correlates with acti-
vation of the cell-cycle inhibitor p21 (Cip1/Waf1) [24,34]
and is regulated by cell-density-dependent post-transla-
tional processes [22]. The expression of both p21 and CCN3
is regulated by the tumour suppressor p53 [35]. Because
CCN1 and CCN2 often exhibit expression patterns oppo-
site to those of CCN3 during development [11] and in
cultured cells [30], the regulation of cell proliferationmight
involve a subtle balance of negative and positive signals
induced by different members of the CCN family [5,29].
Tumourigenesis
Abnormal levels of most CCN family members are associ-
ated with tumour development [6]. Recent data [24]
suggest that enhanced or reduced expression of CCN
proteins in tumours results from deregulated transcrip-
tional and post-transcriptional regulatory processes.
Whereas full-length CCN proteins can exhibit anti-prolif-
erative behaviour, truncated CCN isoforms can act as
tumourigenic agents [7] and promote tumourigenesis.
Similar effects are observed when inappropriate levels of
CCN proteins are produced [36]. Indeed, evidence links all
CCN family members to tumourigenic effects [5,6,29,37].
CCN1, CCN2 and CCN4 are expressed at elevated
levels in advanced breast cancers; increased CCN1 levels
are thought to lead to more invasive breast cancers [36].
CCN1 and CCN2 levels are also elevated in pancreatic
tumours; CCN2 expression is linked to malignancy.
Increased CCN2 levels are also present in some brain
tumours [36]. Likewise, CCN4 and CCN6 expression levels
are significantly raised in some colon cancers [36]. By
contrast, expression levels of CCN1–5 are reduced in high
grade chondrosarcomas [4], and CCN3 expression is
reduced in brain tumours [4] and chronic myeloid leukae-
mia [38].
Because CCN3 was the first member of the CCN family
to be associatedwith tumour development [3], it is themost
studied CCN protein with regard to tumour typing and
prognosis [6]. CCN3 expression is upregulated in prostate
and renal carcinomas [7]. Likewise, CCN3 is highly
expressed in both visceral and nodalmelanomametastases
and it has been proposed that it regulates dissemination of
the tumour cells through the interaction of tumour cells
with the ECM [39]. Moreover, CCN3 expression, together
with connexin 43, correlates positively with reduced
tumour cell growth in choriocarcinomas and glioblastomas
[6]. By contrast, another study suggests that progression of
melanoma is associated with CCN3 downregulation; these
differences highlight the complexity of CCN biology in
tumours [40].
Interestingly, the expression of CCN proteins can also
serve as a prognostic tool in human tumours. For example,
* O. Lund et al., abstract A102, CASP5 (the 5th community-wide experiment on the
Critical Assessment of Techniques for Protein Structure Prediction) conference,
California (USA), December 2002.
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CCN2 contribute to glioma tumour progression. CCN1
and CCN2 expression levels also correlate positively with
tumour grade and pathology and are prognostic indicators
of patient survival in these tumours [6]. A significant
correlation was established between CCN1 and CCN2
expression and survival of patients with lung cancer
[41]. In addition, CCN2 expression is an independent
prognostic indicator of both tumour recurrence and overall
survival for intra-hepatic cholangiocarcinoma [42]. CCN4–
6 levels are also of significant prognostic value in breast
cancers [43], and reduced CCN6 expression is strongly
associated with a poor prognosis in 80% of aggressive
inflammatory breast cancers [31]. This lack of CCN6
results in uncontrolled IGF-1-induced cell growth and
tumourigenesis. Indeed, the CCN6 IGFBP domain is
thought to help regulate IGF-1 availability in healthy
tissues [44,45].
In musculoskeletal tumours, including rhabdomyosar-
coma, and cartilage tumours, CCN3 expression correlates
positively with tumour differentiation. By contrast, in
Ewing’s sarcoma, CCN3 expression is associated with a
higher risk for metastasis [11] and a poor survival prog-
nosis [46,47]. Therefore, the prognostic value of CCN
proteins in tumour biology is now opening promising ave-
nues for molecular diagnosis, typing and therapy [30,48].
The domain structure of the CCN proteins
The variety of biological functions assigned to the CCN
proteins is in agreement with the proposed model that
CCN proteins are adaptor molecules involved in multi-
molecular complexes that coordinate and integrate signal-
ling between extracellular ligands and their receptors
[7,11]. Therefore, a prediction of CCN protein structures,
comparing the spatial organization of their constituent
modules, might provide crucial information regarding
their pleiotropic functions. The domain structure of the
CCN proteins resembles many ECM proteins because they
are constructed from a library of commonly used domains
[49]. Although the domains have been classified through
recognizable motifs, the exact role of each domain in CCN
biology is not fully understood. Here, we discuss each
domain, focusing on how the predicted three-dimensional
structure of the domain might influence function.
The IGFBP domain
The mammalian IGFBP family consists of six IGFBPs
(1–6) that bind IGFs with high affinity (KD 0.1 nM) to
control their transport, localization and metabolic break-
down. The indirect control of IGF function implicates
IGFBPs in many important cellular functions, including
cell cycle progression, cell proliferation, cell death, cell
differentiation, amino acid and glucose uptake, hormone
and neurotransmitter secretion, chemotaxis and parts of
the immune response [50].
The IGFBP proteins are multidomain proteins with
distinct cysteine-rich N- and C-terminal domains linked
by a variable linker region. The N-terminal globular
domain contains 12 conserved cysteine residues, and the
C-terminal domain contains an additional six conserved
cysteine residues [51]. The linker region has a variablelength and amino acid composition among family members
and contains several sites vulnerable to protease degra-
dation [51,52]. High-affinity IGF binding results from both
the N- and C-terminus working together in concert, akin to
a set of jaws that can contain the entire IGF molecule.
Little information is available concerning the exact role
played by the IGFBP domain in CCN function. The IGFBP
domain of the CCN proteins shares strong sequence sim-
ilarity to the N-terminal domain of traditional IGFBPs [1]
(Figure 1); this similarity has resulted in some CCN
proteins being classified as additional IGFBPs or as
IGFBP-related proteins (IGFBP-rPs) [51]. Despite the
similarity with the N-terminal domains, the CCN proteins
bind IGF poorly, in the order of 100-fold lower than the
traditional IGFBPs. This low binding affinity probably
results from the lack of an IGFBP C-terminal-like domain
[53]. The construction of a recombinant chimera between
CCN3 and IGFBP3 established that the CCN3 IGFBP
module cannot substitute for the IFGBP3 amino-proximal
sequence for IGF binding [54], an observation that
reinforces the possibility that the IGFBP module of CCN
proteins might be involved at another level of IGF signal-
ling. It is possible that interactions with IGF could con-
tribute to some types of CCN-dependent tumourigenesis.
The close identity between the N-terminal domains of
traditional IGFBPs and CCNproteins allows a structure to
be predicted by the CPH model (World Wide Web Predic-
tion) server*. The models were built using an 80 amino
acid stretch of IGFBP4 with which they shared 30%
sequence identity (PDB code 1DSP) [55]. The 80 residue
IGFBP N-terminal domain has an approximately L-
shaped appearance and can be divided into two subdo-
mains connected by a short stretch of coil (Figure 2). The
first subdomain has a novel fold with a two-stranded anti-
parallel b-sheet and two parallel loops stabilized by a
ladder of disulphide bonds [55]. The b-sheet and the dis-
ulphide ladder both form a flat plane, the so-called ‘palm’ of
the molecule, and in the traditional IGFBPs, the N-term-
inal residues protrude forming a ‘thumb’ on the IGFBP-
binding domain. This thumb plays an important role in
IGF binding, forming several important hydrophobic inter-
actions with aromatic residues within the IGF molecule
[55]. The second subdomain contains the IGF-binding site
and is a globular domain centred around a three-stranded
anti-parallel b-sheet strengthened by an internal disul-
phide bridge that links strands 1 and 3 [55–57]. The palm,
which contains the conserved GCGCCxxC motif, forms a
rigid base that supports and separates the thumb sequence
and the globular subdomain, maintaining the correct con-
formation to allow IGF binding [55].
The IGFBP domainmodels generated by theCPHmodel
server vary slightly among the four CCNproteins for which
models were established (Figure 3); CCN4 and CCN5 could
not be modelled. The models for CCN1, CCN2 and CCN3
resemble that of the IGFBP4 structure: they maintain the
disulphide bonded ladder (containing three disulphide
bonds) as well as a flat palm region and the cleft at the
IGF-binding site. The CCN6 model, unlike the others,465
Figure 2. The IGFBP domain. The models of the IGFBP domain of (ii–iv) CCN1–3
and (v) CCN6 alongside (i) the IGFBP4 structure ([PDB code 2DSP) [55]. The models
maintain the L-shaped structure with a disulphide supported ladder-like structure
forming one lobe and a b-sheet-containing section forming the second lobe. In the
surface representations of the IGFBP domains red represents negative charge and
blue represents positive charge. The long protruding thumb region in IGFBP4 is
clearly visible but could not be modelled for any of the CCN proteins. This figure
was drawn using PyMOL (http://pymol.sourceforge.net/).
Review Trends in Biochemical Sciences Vol.33 No.10lacks the disulphide ladder and the flat palm region.
However, this difference might be due to limitations with
modelling and an inability to thread the first half of the
IGFBP domain rather than a meaningful biological differ-
ence.
Notably, there are some differences between the CCN
models and the IGFBP4 structure. For example, the N-
terminal thumb region, which in IGFBP4 harbours an
‘XhhyC motif’, where ‘h’ is a hydrophobic amino acid,
and ‘y’ is positively charged [55–57], is absent in CCN466proteins. Although both CCN2 and CCN3 have positively
charged residues directly preceding the cysteine, they have
glutamine residues in place of one of the hydrophobic
residues. The importance of this difference, if any, is
unknown.
Although the models of CCN1–3 are all similar and
share the same disulphide bonding pattern and general
core structure, they display different surface electrostatic
charges (Figure 3). As one of the underlying questions
about the CCN proteins is how they interact with different
binding partners while maintaining such close sequence
and presumably structural similarity, subtle changes in
the surface charge and the areas in which they interact
with binding partners might allow CCN proteins to differ-
entiate between their specific partners.
The von Willebrand factor C repeat
The von Willebrand factor type C domain (VWC), also
referred to as chordin-like cysteine rich (CR) repeats, is
a common motif found in >500 ECM proteins [58]. This
repeat is typically 70–100 amino acids in length and
contains ten conserved cysteine residues and a pair of
cysteine-containing motifs. The first of these, C2xxC3xC4,
lies towards the middle of the repeat, and the secondmotif,
C8C9xxC10, lies towards the end (in both cases the numbers
refer to the ten cysteine residues that comprise the VWC
repeat). In the CCN protein family, these motifs are con-
served, but both motifs are extended with an extra residue
between C2 and C3 and two extra residues between C9 and
C10 [1] (Figure 1). However, four cysteine residues are
missing (numbers 2, 6, 8 and 9) in CCN6 [1].
The VWC repeat is one of the most commonly occurring
motifs and is found in many proteins of variable functions
including the CCN proteins, procollagen, thrombospondin,
von Willebrand factor, glycosylated mucins and neuralin
[6]. Unlike the lone copy present in the CCN family of
proteins, the VWC domain is typically present in multiple
copies in other proteins [59,60]. In most proteins, the VWC
repeat regulates bone morphogenic proteins (BMPs) and
TGF-b signalling [59,61–63]. BMPs are important growth
factors that influence bone and cartilage growth, skeletal
patterning and the formation of several organs, such as the
kidney, lungs and teeth [64,65]. The ability of the VWC
domain to bind TGF-b and BMP suggests that it plays a
role in some of the biological functions associated with
CCN proteins. In proteins that contain multiple VWC
domains, growth factor affinity varies among repeats,
and the activity of intact proteins can be asmuch as tenfold
higher than that for an individual repeat, suggesting a
complicated means of regulation [66]. The significance of
this effect on the function and regulatory activity of the
single VWC domain in CCN proteins is unknown. How-
ever, it is likely that the sequence diversity among the
VWC-containing proteins accounts for the variable sub-
strate specificity. For example, CCN2 binds BMP4 and
TGF-b1, although with a higher affinity for BMP4 (KD
5 nM compared with 30 nM for TGF-b1) [59], whereas
chordin binds BMP-4, -5 and -6 as well as TGF-b1 and
TGF-b2 [62].
CCN2might function as a chaperone for TGF-b1; there-
fore, the low-affinity binding might facilitate its transport
Figure 3. The VWC domain. The 70 residue stretch of the VWC domain from (ii–vii) the six CCN proteins alongside (i) the structure of the VWC domain from human
chordin (PDB code IU5 M) [70] shown as ribbon and electrostatic surface models. The top half of the molecule with the two b-sheets is the first subdomain, and the lower
half of the molecule held together only by disulphides is the part that resembles fibronectin and might be involved in growth factor binding. In the electrostatic surface
representations of the VWC domains, positive charge is shaded blue and negative charge is shaded red. The differences in surface charge might contribute to the different
biological functions observed for CCN family members. This figure was drawn using PyMOL (http://pymol.sourceforge.net/).
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[67]. The CCN2–TGF-b1 interaction also enhances TGF-b1
signalling, and less TGF-b1 is required to stimulate its
downstream partners [59]. By contrast, CCN2–BMP4
binding is inhibitory [59]. Recent reports indicate that
CCN3–BMP2 binding inhibits BMP2-induced osteoblast
differentiation [68]. Related to its interaction with growth
factors, the CCN3 VWC domain might participate in some
aspects of cell development and tumour formation, perhaps
by mediating its oligomerization. In vonWillebrand factor,
the VWC domain mediates large scale oligomerization,
although only after an initial dimerization step has taken
place. InCCNproteins, the CT domain has been implicated
in dimerization, which could result in larger oligomers
of CCNmolecules through subsequent VWC domain inter-
actions [4,5,69].
The VWC domains from CCN1–6 were modelled using
the CPH model server* using the NMR structure of a
chordin VWC domain (PDB code IU5 M) [70] as the tem-
plate. Aside from CCN6, each CCN protein contained the
conserved cysteines of the domain. The chordin VWC
domain forms two subdomains (Figure 3): the first com-
prises a short two-stranded anti-parallel b-sheet followed
by a three-stranded anti-parallel b-sheet. The triple sheet
is supported by a disulphide bridge between strands 2 and
3 and a second disulphide bond formed between strand 2
and the first strand of the two-stranded sheet. The second
subdomain has no predicted secondary structure but is
constrained by three disulphides formed between the
remaining six cysteine residues. It forms a novel fold that
shows some structural similarity to fibronectin. This find-
ing could suggest that the interactions between the CCN
proteins and TGF-b follow a similar pattern to that seenbetween VEGF and fibronectin [70]. Two regions in BMPs,
a ‘knuckle’ and ‘wrist’, are important for receptor binding,
and some results suggest that the negative activity that is
elicited by VWC repeats might result from interference
with the interactions between the ‘knuckle epitope’ and
BMP-receptor II [70,71]. In considering the interactions
between TGF-b, BMP-4 and the VWC domain in CCN
proteins, it is impossible to predict the exact nature of
the interaction or the location of the VWC domain until
further biological/structural data become available.
The VWC domain in CCN proteins consists of an upper
section comprising b-sheets and a more or less unstruc-
tured lower domain held together by disulphide bonds
(Figure 3). The conserved cysteines in CCN1–5 all follow
the same binding pattern: two disulphide bonds between
the b-sheets and three more holding the unstructured
fibronectin-like domain together [70]. Although each
CCN protein is similar in VWC domain arrangement, their
electrostatic surfaces (Figure 4) show a wide range of
differences. CCN1 and to a lesser extent CCN5 are prim-
arily negatively charged on the front face of the VWC
domain, whereas CCN4 is primarily positively charged.
The remaining molecules have a mix of charges on their
surface. The large differences in surface charge could affect
the different behaviours of CCN family members or their
inter- or intra-molecular oligomerization patterns.
The TSP-1 domain
The thrombospondin repeat domain is a 55 residue con-
sensus sequence named for the ECM glycoprotein TSP-1
that contains repeats of three distinct domains within a
primarily linear structure [72]. These include three throm-
bospondin type-1 repeats (TSR-1), three epidermal growth467
Figure 4. The CCN TSP domain. The 40 residue models of the TSP domain of (ii–vii) the CCN family shown alongside (i) the TSP-1 domain of thrombospondin (PDB code
1LSL) [84], shown as both ribbon models and electrostatic surface models. The two b-strands and the third unordered strand form the basis of the domain. Several residues
that could form the ‘CWR’ layers are also shown in stick form. The first cysteine disulphide formation that forms the ‘top’ layer is not present in the model but is present in
the protein sequence, and the unpaired half of it is shown at the top of the third strand. There are also two arginine residues and a tryptophan present that can form the CWR
layers. The additional CWR layers in thrombospondin can also be observed. In the model structures of the TSP domains from the CCN family shown, positive charge is
shaded blue and negative charge is shaded red. In each case, there is a large patch of positive charge that forms a groove that might permit interactions with heparin or
other sulphated proteoglycans. This figure was drawn using PyMOL (http://pymol.sourceforge.net/).
Review Trends in Biochemical Sciences Vol.33 No.10factor-like repeats (thrombospondin type-2 repeats) and
seven aspartic-acid-rich repeats (thrombospondin type-3
repeats) [73].
The TSR-1 repeat is a common motif; 187 TSR
sequences are foundwithin the human genome and numer-
ous others are found in other eukaryotic organisms [73].
TSR-1-containing molecules are wide ranging in scope and
include, in addition to the CCN family, thrombospondins
and spondins, papilin, ECM ADAMTS (a disintegrin and
metalloproteinase with thrombospondin motif) and comp-
lement pathway proteins (C6, C7, C8A, C8B, C9 and
properdin) [73,74]. Within this wide range of proteins,
the TSP-1 domain binds many different targets, including
collagen V [75], fibronectin [76], CD36 [77], TGF-b [78] and
heparin [79], thereby eliciting many distinct biological
functions. The functions of the thrombospondin TSR
repeats have been extensively studied; four main functions
are now attributed to them: (i) cell attachment sites in
signalling and adhesion, (ii) inhibition of angiogenesis,
(iii) protein-binding sites for a range of growth factors
and other ECM proteins and (iv) glycosaminoglycan
(GAG)-binding sites [80].
In the CCN family, the exact function of the TSP-1
domain remains unclear, although it is similar to TSRs
in other proteins [37]. The ability of the TSP-1 domain to
bind sulphated glycoconjugates [81] and some integrins468[17] further suggests a role in adhesion or interactions with
the ECM. As the CCN proteins are potent modulators of
angiogenesis, it is also likely that the TSP-1 domain is an
important module in the manipulation of angiogenesis.
VEGF interacts with CCN2 through both the TSP-1 and
CT domains [82]. The CCN2 TSP-1 domain interacts only
with the heparin-binding VEGF-A165 isoform in an anti-
angiogenic mode of action, whereas the CT domain inter-
acts with both VEGF-A165 and VEGF-A121. The nature of
the TSP–VEGF-A165 interaction suggests a mechanism
through which the TSP-1 domain binds VEGF-A165 and
sequesters it away from its receptors. This anti-angiogenic
effect can also be removed after matrix metalloprotease
(MMP)-mediated CCN2 cleavage [82,83].
Many TSRs bind TGF-b. For thrombospondin, this
interaction requires the RFK tripeptide sequence located
between the first and second TSRs. However, the TSP-1
domains in all of the CCN proteins lack this sequence.
Therefore, another module might be involved with TGF-b
binding [84], or the TSP domainmight work synergistically
with another of the TGF-b-binding domains.
On the sequence level, the TSP-1 domain shares a high
degree of similarity with the other members of the TSR
superfamily. It is a short domain of 60 amino acids with
six conserved cysteine residues, the conserved motif
CSxTCG (although CCN3 has the motif CSxSCG) and a
Review Trends in Biochemical Sciences Vol.33 No.10commonly conserved arginine and a tryptophan residue at
the N-terminal of the domain [1,84] (Figure 1).
The three-dimensional structures of the TSR repeats
from thrombospondin [84] and F-spondin [85] have been
determined by X-ray crystallography and nuclearmagnetic
resonance spectroscopy (NMR), respectively. Each individ-
ual TSR is composed of a small three-stranded anti-paral-
lel b-sheet (15  20  55 A˚) that is twisted slightly into
a right-handed helical shape [84] (Figure 4). The three
disulphide bonds present in each TSR repeat link the turns
together to stabilize the structure; the disulphide bonding
pattern can be used to divide the TSP family into two broad
groups [84]. The network of bonds in the predicted CCN
TSP-1 structures place them into group 2 alongside F-
spondin, thrombospondin-related anonymous protein
(TRAP) and the various proteins of the complement system
[84]. Thrombospondin also contains a ladder-like arrange-
ment of hydrogen bonds formed primarily by tryptophan
and arginine residues, in conjunction with the supporting
disulphide bonds, which give rise to the CWR layers,
named after the residues that form the hydrogen bonds.
The TSP domain in the CCN family lacks the WxxWxxW
motif and has only one tryptophan. Similarly the CCN
TSRs lack a pair of conserved arginine residues and, in
most cases, contain a single arginine residue. This finding
suggests that the CCN family TSP domains have fewer
CWR layers criss-crossing the b-sheet. Although little is
known about the binding properties of substrate to TSRs,
they bind heparin, most likely through interactions with
the negatively charged sulphate groups. In the structure of
the thrombospondin TSR, the groove of the TSR helix is
approximately the correct size for the accommodation of
two heparin molecules and contains a large stretch of basic
residues along the groove [84].
A predicted structure of the TSP-1 domains of all six
CCN proteins was obtained using the CPH modelling
server [55]; the predicted structure comprised 45 amino
acids of the TSP domain out of the 70 amino acids in the
domain (Figure 4). The models used were the malaria
TRAP protein TSP domain (PDB code 2BBX) [85] for
CCN1, 3, 5 and thrombospondin-1 (PDB code 1LSL) [84]
for CCN2, 4 and 6 (based on which template produced the
best model). All six models display the same spatial
arrangement as existing TSP domains and have a three-
stranded anti-parallel b-sheet. Strand A is irregular, but
still forms a network of b-sheet-like bonds between strands
B and C. However, unlike the structures of the F-spondin
and thrombospondin TSRs, the predicted structure of the
CCNTSP domains do not have such an extensive system of
hydrogen bonds. In all six models, only a single tryptophan
and two arginine residues are present. The three disul-
phide bonds that hold the loops together above and below
the sheet are also present in the CCN domains, although in
most of the models (except for CCN5), one or more are
missing owing to the limitations of the modelled structure.
Although the models do not show all of the disulphides, if
they are extended to include the complete sequence of the
TSP domain, the missing cysteines would be in the correct
places (based on amino acid sequence alignment) to form
the appropriate disulphide bonds. The electrostatic sur-
faces of the models (Figure 4) indicate that the stronglyconserved basic face of the molecule probably interacts
with heparin sulphate in a manner analogous to throm-
bospondin. Because the positively charged groove is con-
served in all six of the models, it is possible that all of the
CCN proteins use the TSP domain in a similar manner for
binding heparin or sulphated proteoglycans to modulate
cell adhesion and maintain ECM composition.
TSP domains interact with TGF-b [74], and, because
interactions with TGF-b are central to many functions of
CCN proteins, it is possible that these interactions might
be coordinated by the TSP domain working in conjunction
with the other CCN protein domains [3,4,8]. The TSP
domain, like other CCN domains, might be involved in
cancer biology [7]. Indeed, some studies have linked CCN
proteins with mutant or missing TSP domains with color-
ectal and gastric carcinomas [6] and Wilm’s tumours
[86,87].
The cysteine knot C-terminal domain
The CT domain is similar to those found in many extra-
cellular matrix proteins, including Drosophila melanoga-
ster slit, the von Willebrand factor, several mucins, Norrie
disease protein and a wide variety of small growth factors,
including VEGF, TGF-b, BMPs, nerve growth factor (NGF)
and platelet-derived growth factor (PDGF) [1,88]. This
domain is thought to mediate several CCN protein func-
tions. Because it contains a cysteine knot motif of six
conserved cysteine residues, it is thought to act as a
dimerization module in a manner analogous to that seen
in other growth factors, for example NGF, TGF-b or PDGF
[1,4,89]. CT-domain-mediated interactions can be hetero-
dimeric: the CCN3 and CCN2 CT domains interact in
glutathione S-transferase pull-down assays [90]. CT-
domain-mediated dimerization probably works in concert
with TSP-domain-mediated oligomerization to give rise to
the large CCN oligomers that have been detected in all
preparations of CCN proteins so far described [37].
Several non-CCN protein CT domain interacting part-
ners have been identified; these proteins might yield clues
about CT domain function in CCN biology. Whereas the
TSP domain is thought to bind heparin sulphated proteo-
glycans (HSPGs), the CT domain is involved in heparin
binding. In addition, except for CCN4, which lacks the CT
domain, the CCN proteins have a high number of basic
residues at the CT domain N-terminus that follow the
general heparin-binding pattern of xBBxBx (where B is
a basic residue and x is usually not charged) [91]. The CT
domain, in concert with the TSP domain, might be an
important factor in directing how CCN proteins control
and manipulate adhesion processes and the ECM compo-
sition and mediate cell adhesion [4]. Interactions with
Notch 1, a key mediator of cellular differentiation [92],
and the apoptosis-inducing integrin a6b1 [6] support a
second role for the CT domain as a regulator of mitogenic
signalling. Indeed, the isolated CCN2 CT domain performs
this role [93]. The CCN3 CT-domain performs an essential
role in the anti-proliferative function of CCN3, because in
isolation this domain can prevent mesenchymal stem cell
proliferation and differentiation [35]. The CCN3 CT
domain is also thought to contain sequences that are
involved in the nuclear addressing of CCN variants that469
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are potential negative regulators of transcription involved
in tumourigenesis, the CT domain is an essential element
that participates in the physiological balance between the
distinct biological activities of intra- and extra-cellular
CCN3 proteins.
The sheer number of biological functions tied to the
heparin- and integrin-mediated receptors has resulted in
suggestions that HSPGs and integrins should be con-
sidered as the functional receptors for the CCN family
[12]. In addition to the pathways governed by HSPGs
and integrins, the CT domain also modulates the Wnt
signalling pathway through interactions with the low-
density lipoprotein (LDL) receptor protein 6 (LRP6) [12].
Although incompletely characterized, each of these
roles suggests that the CT domain is important for CCN
function.Figure 5. The CT domain. The 50 residue partial models of (ii–iv) the CT domains of CC
knot is visible with two disulphides forming the ring and a fifth cysteine protruding thro
surface diagrams are also shown (red illustrates negative charge and blue illustrates pos
This figure was drawn using PyMOL (http://pymol.sourceforge.net/).
470On the basis of its sequence, the CT domain is thought to
be related to the ‘cysteine knot family’ of proteins, which
encompasses the TGF-b-related growth factors and Norrie
disease protein. Therefore, it is likely that it will interact
with its partners in a similar manner [1,88]. The cysteine
knot growth factors, although showing some sequence
divergence, all share the same core three-dimensional
structure [88]. This structure comprises an eight-mem-
bered ‘cysteine knot’ ring with two adjacent two-stranded
anti-parallel b-strands and sometimes a short a-helix on
the opposite side of the cysteine knot [88,89,95]. The
cysteine knot is formed from a ring of eight residues linked
by two disulphide bonds with a third bond through the
centre of the knot [89,96]. In both NGF and TGF-b, the
disulphide that forms through the knot is interchain, and a
different cysteine directs dimer formation. By contrast, in
PDGF, the cysteine coming through the centre of the knotN1–3 and (i) the structure of BMP7 (PDB code 1LXI) [100]. In each case the cysteine
ugh the knot, available for either inter- or intra-molecular interactions. Electrostatic
itive charge) showing the subtle differences between the closely related molecules.
Box 1. Outstanding questions
(i) Could the differences in expression patterns, such as CCN1 and
CCN2 being immediate early proteins, whereas CCN3 is not, or
the differences in cellular locations and tissue specificity of CCN
proteins provide some explanation for their apparently conflict-
ing functions?
(ii) Does the presence of multiple binding sites spread over several
domains and the altered biological activity of truncated CCN
proteins support a synergistic inter-domain approach to sub-
strate binding and function?
(iii) As the CT domain can form both homo- and hetero-dimers and
the VWC domain might facilitate the formation of higher order
complexes, could some CCN protein functions be orchestrated
by larger complexes of CCN molecules?
(iv) Are the linker regions important for the biology of CCN proteins,
either through proteolytic control or flexibility regarding hinges,
thereby allowing distant domains to interact with each other?
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addition to the ability to form strong dimers, TGF-b family
members (including the BMPs) display high affinity for
heparin and HSPGs [95,97]. The heparin-binding site
occurs between the tips of the b-sheet loops and is located
around a collection of positively charged residues. This
binding site is primarily made up of four basic residues on
the loop of the first b-sheet and then a single Arg/Lys on the
loop of the second sheet [95,97]. Although this part of the
sequence could not be modelled for all of the CCN proteins,
they all possess this string of basic residues at the N-
terminal portion of the CT domain.
The sequence divergence among the cysteine knot
family could indicate whymodelling the CT domain proved
difficult (Figure 1). The Phyre homology and recognition
server [98,99] could build only partial models of the CT
domain for CCN1 using BMP7 as a template (PDB code
1LXI)] [100], CCN2 using TGF-b3 (PDB code 1KTZ) [101]
and CCN3 using TGF-b1 as a template (PDB code 1KLA)
[102]. In all cases, only 50 residue models could be
constructed (Figure 5). In each case, the first 30 residues
could not be modelled; these 30 residues include the basic
N-terminal end of the domain and a long loop containing b-
strands. However, the cysteine knot is intact with two
disulphides forming the ring and a fifth cysteine protrud-
ing through the ring available for the formation of a third
disulphide bridge. Without a complete three-dimensional
structure, it is impossible to know whether this third
disulphide will form an intra-molecular bond within the
CT domain, or an inter-molecular bond and bind other
cysteine-knot-containing growth factors, or a dimer with
other CCN molecules [90]. Although the CCN CT domains
appear to have a similar arrangement, the electrostatic
surfaces (Figure 5) show some differences, and this finding,
coupled with a fairly diverse sequence apart from the
conserved cysteines, might account for the wide range in
CT domain ligands and binding partners.
Concluding remarks
CCN proteins participate in many cellular functions. Yet
owing to the sheer scope of their action, it is unlikely that
their function is a direct result of their individual domains
acting independently, but rather represents a cumulative
effect between multiple domains and receptors. Indeed the
often opposing physiological functions of the structurally
similar proteins supports this notion [3,4,11]. Although
differences in amino acid sequence can lead to large vari-
ations in surface charge and substrate binding, the elucida-
tion of the three-dimensional structure of individual domain
ormultiple domains is necessary to answermany remaining
questions (Box 1) surrounding the CCN family of proteins.
An initial comparison of the primary structure of the six
known CCN proteins could suggest that they possess
redundant biological functions. However, the available
experimental data strongly argue against that idea. The
tight spatiotemporal regulation of the expression of CCN
proteins [11] indicates that they are required at precise
time frames. Interestingly, the expression patterns of CCN
proteins show only partial overlap, which suggests that
they might act sequentially. A thorough analysis of the
regulatory processes involved in the coordinated expres-sion of CCN genes is essential for a better understanding of
the functions of the proteins they encode.
It has been proposed that the biological properties of
CCN proteins are highly dependent upon the bioavailabil-
ity of interacting ligands and proteins [11]. Accordingly,
the tetramodular organization of the CCN proteins pro-
vides a unique situation, because each of the four consti-
tutive modules could potentially interact independently
with a handful of partners. Therefore, the variety of bio-
logical functions in which the CCNproteins participate can
be viewed as the result of combinatorial events, the like-
lihood of which depends upon the presence of the various
partners at precise times and locations [11]. Importantly,
CCN proteins might act in concert and exert either syner-
gistic or antagonistic functions. Indeed, recent research
established that coordinated and interdependent CCN
protein expression is required for chondrogenesis and
osteogenesis [33,103].
Overall, the CCN proteins can be compared to non-
identical ‘sextuplets’. Although they sharemany structural
features, subtle differences in their interactions with bind-
ing partners render them functionally unique. The ability
of CCN proteins to interact physically with various regu-
latory partners also places them at the interface of key
signalling pathways. Whether the CCN proteins partici-
pate in the control and coordination of these signalling
pathways and how this is achieved remain open and
challenging questions.Acknowledgements
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